Unraveling the Influence of Common von Willebrand factor variants on von Willebrand Disease Phenotype: An Exploratory Study on the Molecular and Clinical Profile of von Willebrand Disease in Spain Cohort.


Journal

Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063

Informations de publication

Date de publication:
Mar 2020
Historique:
entrez: 6 3 2020
pubmed: 7 3 2020
medline: 29 12 2020
Statut: ppublish

Résumé

The clinical diagnosis of von Willebrand disease (VWD), particularly type 1, can be complex because several genetic and environmental factors affect von Willebrand factor (VWF) plasma levels. An estimated 60% of the phenotypic variation is attributable to hereditary factors, with the ABO blood group locus being the most influential. However, recent studies provide strong evidence that nonsynonymous single nucleotide variants (SNVs) contribute to VWF and factor VIII phenotypic variability in healthy individuals. This study aims to investigate the role of common VWF SNVs on VWD phenotype by analyzing data from 219 unrelated patients included in the "Molecular and Clinical Profile of von Willebrand Disease in Spain project." To that end, generalized linear mixed-effects regression models were fitted, and additive and epistatic analyses, and haplotype studies were performed, considering five VWD-related measures (bleeding score, VWF:Ag, VWF:RCo, factor VIII:C, and VWF:CB). According to these analyses, homozygotes: for p.Thr789Ala(C) would be expected to show 39% higher VWF:Ag levels; p.Thr1381Ala(C), 27% lower VWF:Ag levels; and p.Gln852Arg(C), 52% lower VWF:RCo levels. Homozygotes for both p.Thr789Ala(C) and p.Gln852Arg(T) were predicted to show 185% higher VWF:CB activity, and carriers of two copies of the p.Thr1381Ala(T)/p.Gln852Arg(T) haplotype would present a 100% increase in VWF:RCo activity. These results indicate a substantial effect of common

Identifiants

pubmed: 32135566
doi: 10.1055/s-0040-1702227
doi:

Substances chimiques

von Willebrand Factor 0
F8 protein, human 839MOZ74GK
Factor VIII 9001-27-8

Banques de données

ClinicalTrials.gov
['NCT02869074']

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

437-448

Subventions

Organisme : H13-000845
ID : Baxalta US Inc.
Organisme : PI15/01643
ID : Instituto de Salud Carlos III (ISCIII)

Informations de copyright

Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

None declared.

Auteurs

Nina Borràs (N)

Congenital Coagulopathies, Banc de Sang i Teixits, Barcelona, Spain.
Transfusional Medicine, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.

Iris Garcia-Martínez (I)

Congenital Coagulopathies, Banc de Sang i Teixits, Barcelona, Spain.
Transfusional Medicine, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.

Javier Batlle (J)

Department of Hematology, Complexo Hospitalario Universitario A Coruña, INIBIC, A Coruña, Spain.

Almudena Pérez-Rodríguez (A)

Department of Hematology, Complexo Hospitalario Universitario A Coruña, INIBIC, A Coruña, Spain.

Rafael Parra (R)

Congenital Coagulopathies, Banc de Sang i Teixits, Barcelona, Spain.
Transfusional Medicine, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.

Carme Altisent (C)

Transfusional Medicine, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.

María Fernanda López-Fernández (MF)

Department of Hematology, Complexo Hospitalario Universitario A Coruña, INIBIC, A Coruña, Spain.

Joana Costa Pinto (J)

Department of Hematology, Complexo Hospitalario Universitario A Coruña, INIBIC, A Coruña, Spain.

Fernando Batlle-López (F)

Department of Research, Lapisoft SA, A Coruña, Spain.

Ana Rosa Cid (AR)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Santiago Bonanad (S)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Noelia Cabrera (N)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Andrés Moret (A)

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

María Eva Mingot-Castellano (ME)

Department of Hematology, Hospital Regional Universitario de Málaga, Málaga, Spain.
Hospital Universitario Virgen del Rocio, Sevilla, Spain.

Nira Navarro (N)

Department of Hematology, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.

Rocío Pérez-Montes (R)

Department of Hematology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Shally Marcellini (S)

Department of Hematology, Salud Castilla y León, Segovia, Spain.

Ana Moreto (A)

Department of Hematology, Hospital Universitario Cruces, Barakaldo, Spain.

Sonia Herrero (S)

Department of Hematology, Hospital Universitario de Guadalajara, Guadalajara, Spain.

Inmaculada Soto (I)

Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain.

Núria Fernández-Mosteirín (N)

Department of Hematology, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Víctor Jiménez-Yuste (V)

Department of Hematology, Hospital Universitario La Paz, Madrid, Spain.

Nieves Alonso (N)

Department of Hematology, Hospital Infanta Cristina, Badajoz, Spain.

Aurora de Andrés-Jacob (A)

Department of Hematology, Complexo Hospitalario Universitario Santiago de Compostela, Spain.

Emilia Fontanes (E)

Department of Hematology, Hospital Universitario Lucus Augusti, Lugo, Spain.

Rosa Campos (R)

Department of Hematology, Hospital Jerez de la Frontera, Cádiz, Spain.

María José Paloma (MJ)

Department of Hematology, Hospital Virgen del Camino, Pamplona, Spain.

Nuria Bermejo (N)

Department of Hematology, Hospital San Pedro de Alcántara, Cáceres, Spain.

Rubén Berrueco (R)

Department of Hematology, Hospital Sant Joan de Deu, Barcelona, Spain.

José Mateo (J)

Department of Hematology, Hospital Sta Creu i St Pau, Barcelona, Spain.

Karmele Arribalzaga (K)

Department of Hematology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.

Pascual Marco (P)

Department of Hematology, Hospital General de Alicante, Alicante, Spain.

Ángeles Palomo (Á)

Department of Hematology, Hospital Regional Universitario de Málaga, Málaga, Spain.

Nerea Castro Quismondo (N)

Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Belén Iñigo (B)

Department of Hematology, Hospital Clínico San Carlos, Madrid, Spain.

María Del Mar Nieto (M)

Department of Hematology, Complejo Hospitalario de Jaén, Jaén, Spain.

Rosa Vidal (R)

Department of Hematology, Fundación Jiménez Díaz, Madrid, Spain.

María Paz Martínez (MP)

Department of Hematology, Hospital Nuestra Sra. de Sonsoles, Ávila, Spain.

Reyes Aguinaco (R)

Department of Hematology, Hospital Joan XXIII, Tarragona, Spain.

Maria Tenorio (M)

Department of Hematology, Hospital Ramón y Cajal, Madrid, Spain.

María Ferreiro (M)

Department of Hematology, Hospital Montecelo, Pontevedra, Spain.

Javier García-Frade (J)

Department of Hematology, Hospital Río Hortega, Valladolid, Spain.

Ana María Rodríguez-Huerta (AM)

Department of Hematology, Hospital Gregorio Marañón, Madrid, Spain.

Jorge Cuesta (J)

Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain.

Ramón Rodríguez-González (R)

Department of Hematology, Hospital Severo Ochoa, Madrid, Spain.

Faustino García-Candel (F)

Department of Hematology, Hospital Universitario Virgen Arrixaca, Murcia, Spain.

Manuela Dobón (M)

Department of Hematology, Hospital Lozano Blesa, Zaragoza, Spain.

Carlos Aguilar (C)

Department of Hematology, Hospital Santa Bárbara, Soria, Spain.

Irene Corrales (I)

Congenital Coagulopathies, Banc de Sang i Teixits, Barcelona, Spain.
Transfusional Medicine, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.

Francisco Vidal (F)

Congenital Coagulopathies, Banc de Sang i Teixits, Barcelona, Spain.
Transfusional Medicine, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona (VHIR-UAB), Barcelona, Spain.
CIBER de Enfermedades Cardiovasculares (CIBERCV), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH